Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

NCT04592653 is registered in ClinicalTrials.gov with Mural Oncology, Inc as lead sponsor.

NCT NCT04592653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3
Lead sponsor
Mural Oncology, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 30, 2020
Completion date
December 31, 2024
Enrollment
78 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor